Cannabidiol Effects on Cortical Excitability: Evidence from a Randomized, Double-Blind, Placebo-Controlled Study
Clinical Takeaway In this controlled trial, neither a low nor a high single dose of CBD directly altered cortical excitability or produced measurable sedation in healthy adults, suggesting CBD may not have meaningful intrinsic anti-seizure activity on…
CBD in Childhood Epilepsy: What the Evidence Actually Shows
Several randomized controlled trials in children and adults with epilepsy syndromes such as Lennox-Gastaut syndrome and Dravet syndrome have demonstrated meaningful reduction in seizures following the administration of cannabidiol.
CBD for Childhood Epilepsy: What the Evidence Actually Shows
In a multicenter open label prospective interventional trial in patients aged 1–30 years with DRE, oral CBD titrated up to 25 mg/kg/day showed 36.5% median percentage reduction in monthly motor seizures after 12 weeks; more than 50% reduction in seizures…
Ameliorating Seizures in Dravet Syndrome: A Review of Newly Approved and Investigational Drugs, RNA and Gene-Based Therapies.
Dravet syndrome (DS) is a severe infantile-onset developmental and epileptic encephalopathy characterised by frequent drug-resistant seizures, cognitive and ...
Cannabidiol as a New Treatment for Rare Forms of Epilepsy
New research shows that cannabidiol (CBD) can treat therapy refractory epileptic encephalopathies. Epilepsy is a chronic neurologic disorder characterized by a predisposition to seizures, with a prevalence of 8.5 per 1,000 people in the United States. It…